These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35153191)

  • 1. Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study.
    Amabile S; Tonella L; Rubatto M; Argenziano G; Babino G; Frascione P; Dika E; Giacomelli L; Parodi A; Quaglino P
    Eur J Dermatol; 2022 Feb; 32(1):126-7. PubMed ID: 35153191
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
    Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
    J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of MEK inhibitors in the treatment of metastatic melanoma.
    Grimaldi AM; Simeone E; Ascierto PA
    Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
    Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.
    Lucas P; Boulinguez S; Sibaud V; Mourey L; Lamant L; Paul C; Meyer N
    Dermatology; 2018; 234(3-4):92-98. PubMed ID: 30110681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
    Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
    Front Immunol; 2021; 12():661737. PubMed ID: 34025662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.
    Mor JM; Heindl LM
    Ocul Oncol Pathol; 2017 Jul; 3(2):133-141. PubMed ID: 28868285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
    Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
    Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.
    De Ryck L; Delanghe S; Jacobs C; Fadaei S; Brochez L; Saerens M
    Acta Clin Belg; 2023 Jun; 78(3):215-222. PubMed ID: 35996969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
    Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
    Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
    BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States.
    van Boemmel-Wegmann S; Brown JD; Diaby V; Huo J; Silver N; Park H
    JCO Oncol Pract; 2022 Jan; 18(1):e163-e174. PubMed ID: 34228489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
    Kiniwa Y; Okuyama R
    Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: A case report.
    Maanaoui M; Saint-Jacques C; Gnemmi V; Frimat M; Lionet A; Hazzan M; Noël C; Provot F
    Medicine (Baltimore); 2017 Jun; 96(25):e7196. PubMed ID: 28640105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
    Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
    Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.
    Carbonnel F; Routier E; Lazure T; Mussini C; Bellanger C; Merklen C; Bejou B; Buisson A; Amiot A; Meyer A; Dong C; Robert C
    Aliment Pharmacol Ther; 2023 Apr; 57(7):792-799. PubMed ID: 36578099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
    Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma-A Retrospective, Real-World Cohort Study.
    Haist M; Stege H; Ebner R; Fleischer MI; Loquai C; Grabbe S
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
    Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
    Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.